Izalontamab brengitecan (BMS-986507), a bispecific antibody–drug conjugate targeting EGFR and HER3 that releases a camptothecin/topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
Bispecific ADC targeting EGFR and HER3; upon receptor binding and internalization, it releases a camptothecin/topoisomerase I–inhibitor payload that induces DNA damage (via Topo I inhibition) leading to tumor cell death, with potential bystander effect.
NO
INDIRECT
BL-B01D1 binds EGFR/HER3 on tumor cells, is internalized, and releases a camptothecin topoisomerase I inhibitor that induces DNA damage; Topoisomerase I is the payload’s enzymatic target, not the antibody-recognized cytotoxic target.
An investigational IgE-class monoclonal antibody targeting folate receptor‑alpha (FRα). It binds FRα on tumor cells and engages FcεRI-bearing immune effector cells to induce ADCC/ADCP and degranulation against FRα-positive ovarian cancer cells.
MOv18 IgE is an IgE-class monoclonal antibody that binds folate receptor‑alpha (FRα) on tumor cells and engages FcεRI-bearing effector cells (and CD23), triggering ADCC/ADCP and degranulation to kill FRα‑positive ovarian cancer cells.
YES
DIRECT
MOv18 IgE binds FRα on tumor cells and engages FcεRI/CD23 on immune effector cells, inducing ADCC/ADCP and cytotoxic degranulation that kills FRα-positive cells.
Intravenous bispecific T‑cell–engaging monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells to redirect T‑cell cytotoxicity against BCMA‑positive cells; evaluated to prevent progression of high‑risk smoldering multiple myeloma.
Bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells, forming an immune synapse to activate TCR/CD3 signaling and redirect T‑cell cytotoxicity (perforin/granzyme) against BCMA‑positive cells, depleting malignant and normal BCMA+ plasma cells.
NO
INDIRECT
The bispecific antibody binds CD3 on T cells to activate them and bridge to BCMA on tumor cells; T cells then kill BCMA+ targets via perforin/granzyme. CD3+ T cells are not targeted for killing.
An investigational IgE-class monoclonal antibody targeting folate receptor‑alpha (FRα). It binds FRα on tumor cells and engages FcεRI-bearing immune effector cells to induce ADCC/ADCP and degranulation against FRα-positive ovarian cancer cells.
MOv18 IgE is an IgE-class monoclonal antibody that binds folate receptor‑alpha (FRα) on tumor cells and engages FcεRI-bearing effector cells (and CD23), triggering ADCC/ADCP and degranulation to kill FRα‑positive ovarian cancer cells.
NO
INDIRECT
MOv18 IgE binds FRα on tumor cells and engages FcεRI on effector cells to trigger ADCC/ADCP and degranulation that kill FRα+ tumor cells; FcεRIα-expressing cells are the effectors, not the targets.
An investigational IgE-class monoclonal antibody targeting folate receptor‑alpha (FRα). It binds FRα on tumor cells and engages FcεRI-bearing immune effector cells to induce ADCC/ADCP and degranulation against FRα-positive ovarian cancer cells.
MOv18 IgE is an IgE-class monoclonal antibody that binds folate receptor‑alpha (FRα) on tumor cells and engages FcεRI-bearing effector cells (and CD23), triggering ADCC/ADCP and degranulation to kill FRα‑positive ovarian cancer cells.
NO
INDIRECT
MOv18 IgE binds FRα on tumor cells and engages Fcε receptors (FcεRI/CD23) on immune effector cells to trigger ADCC/ADCP and degranulation that kill FRα+ tumor cells; CD23-expressing cells are not the targets of killing.